AnaChart › All brokers › Barrington

Barrington analyst ratings and price targets

Ratings and price targets from Barrington analysts, and how many of their targets were reached. Latest call 6 November 2026.

311
Ratings, 12 mo
294
Price targets, 12 mo
6
Analysts, 12 mo
90
Stocks, 12 mo
33.3%
Median upside, 12 mo
2,506
Price targets since 2009

Rating distribution, past 12 months

311ratings
95.2% Buy
4.2% Hold
0.6% Sell

296 Buy, 13 Hold and 2 Sell from 31 October 2025 to 30 October 2026. 57 target raises and 35 cuts.

Track record

48.9%
of 1,858 targets reached within 12 months
119
days, median wait for those reached

Targets set above the share price from 2008 to October 2025. Across all firms the figure is 59.2%. How we measure.

Sectors covered, past 12 months

Healthcare20%
Industrials19%
Communication Services19%
Technology15%
Consumer Cyclical13%
Consumer Defensive9%
Financial Services4%
Basic Materials2%

Share of the 54 stocks with a sector on AnaChart.

Barrington analysts

AnalystRatings, 12 moPrice targetsStocksAvg upsideTargets metLast call
Kevin Steinke
Buy 94%Hold 6%Sell 0%
62442+42%60%6 Nov 2026
Michael Petusky
Buy 93%Hold 5%Sell 2%
64938+43%55%6 Nov 2026
Alexander Paris
Buy 99%Hold 1%Sell 0%
91754+32.3%66%6 Nov 2026
Gary Prestopino
Buy 91%Hold 7%Sell 2%
66565+71.1%53%23 Oct 2026
Vincent Colicchio
Buy 98%Hold 3%Sell 0%
57233+40.9%60%30 Jun 2026
Patrick Sholl
Buy 96%Hold 4%Sell 0%
15628+41%49%15 Jun 2026

Analysts with a call in the past 12 months, latest first. Price targets, upside and targets met are each analyst's full Barrington record, as on AnaChart stock pages, shown from 5 targets. Updated daily.

Latest ratings and price targets

DateStockAnalystActionPrice targetRating
6 Nov 2026CMPRKevin SteinkeRaised$95 → $102Buy
6 Nov 2026HAEMichael PetuskyRaised$140 → $145Buy
6 Nov 2026STRAAlexander ParisCut$95 → $0Buy
6 Nov 2026USPHMichael PetuskyRaised$98 → $110Buy
26 Oct 2026XRAYMichael PetuskyCut$17 → $13Buy
23 Oct 2026LKQGary PrestopinoCut$60 → $0Buy
23 Oct 2026LRNAlexander ParisCut$125 → $115Buy
16 Oct 2026OPKMichael PetuskyTarget set$2.25Hold
7 Oct 2026OPCHMichael PetuskyCut$42 → $0Buy
29 Sep 2026LFCRMichael PetuskyCut$6.50 → $0Buy
11 Sep 2026ACVAGary PrestopinoCut$7 → $0Buy
11 Sep 2026CPRTGary PrestopinoTarget set$40Hold
12 Aug 2026HRBAlexander ParisRaised$50 → $60Buy
10 Aug 2026TILEAlexander ParisRaised$36 → $45Buy
10 Aug 2026KELYAKevin SteinkeRaised$15 → $20Buy
17 Jul 2026DSGRKevin SteinkeRaised$33 → $35Buy
6 Jul 2026OFIXMichael PetuskyRaised$15 → $17Buy
2 Jul 2026FCAlexander ParisRaised$25 → $30Buy
30 Jun 2026BVSMichael PetuskyMaintained$14Buy
30 Jun 2026CNXCVincent ColicchioCut$38 → $30Buy
26 Jun 2026SNXVincent ColicchioRaised$202 → $325Buy
26 Jun 2026SNXVincent ColicchioRaised$202 → $325Buy
25 Jun 2026EXLSVincent ColicchioTarget set$40Buy
22 Jun 2026CNXCVincent ColicchioMaintained$38Buy
17 Jun 2026HURNKevin SteinkeMaintained$207Buy

The most recent target from each analyst on each stock. Updated daily.

Which targets were reached

Every Barrington target, stock by stock

Which targets were reached, how fast, and each analyst's Performance Score on every stock they cover.

Similar firms

Lake StreetMacquarieArgusHSBCBNP

Barrington: questions

How many ratings has Barrington issued in the past 12 months?

Barrington analysts issued 311 ratings from 31 October 2025 to 30 October 2026: 296 Buy, 13 Hold and 2 Sell, on 90 stocks.

How often are Barrington price targets reached?

48.9% of the 1,858 targets its analysts set above the share price from 2008 to October 2025 were reached within 12 months. For those reached, the median wait was 119 days.

Who are the most active Barrington analysts?

By price targets in the past 12 months: Alexander Paris (71), Gary Prestopino (51), Michael Petusky (51).

Which sectors does Barrington cover most?

Healthcare leads with 20% of the stocks it rated in the past 12 months.

Source: AnaChart records of analyst ratings and price targets. 12-month figures run from 31 October 2025 to 30 October 2026. Analysts and latest calls update daily. AnaChart publishes data about analysts' past calls. It is not investment advice.